You just read:

Tibotec Advances Global Clinical Research Program for TMC435 in HCV; Will Present Four Abstracts Evaluating Safety and Efficacy at EASL

News provided by

Tibotec Pharmaceuticals

Mar 29, 2011, 08:00 ET